Metalloendoprotease activity was identified in retinal homogenates using a synthetic fluorogenic metalloendoprotease substrate and specific metalloendoprotease inhibitors. also prevents release, whereas the amino acid, L-phenylalanine, has no effect. Synthetic carbobenzoxy dipeptide amides which are metalloendoprotease substrates (e.g., CBZ-Gly-Leu-amide, CBZ-Ser-Leu-amide, and CBZ-Gly-Phe-amide) also prevent [3H]glycine release in a dose-dependent and reversible manner. The synthetic dipeptide CBZ-Gly-Gly-amide, however, is not a metalloendoprotease substrate and has no effect on release. The ability of synthetic dipeptides to inhibit neurotransmitter release is amino acid specific, dose dependent, reversible, and matches their ability to interact with characterized metalloendoproteases.
Neurotransmitter
release is achieved through the fusion of synaptic vesicles with the presynaptic membrane resulting in the liberation of vesicle contents into the extracellular space. Neuronal depolarization, either by the action potential or by increasing the extracellular K' concentration, causes a transient influx of calcium into the presynaptic terminal and initiates the fusion of synaptic vesicles with the plasma membrane (Kelly et al., 1983) . Neurotransmitter release thus involves calcium-dependent membrane fusion. The biochemical mechanisms regulating calcium-dependent membrane fusion are incompletely understood but are probably responsible for regulating the timing, extent, and site of fusion.
Metalloendoproteases are metal-dependent proteolytic enzymes which hydrolyze certain peptide bonds distant from the ends of polypeptide chains (Barrett, 1977 and Strittmatter, 1983) and in neurotransmitter release at the neuromuscular junction (Baxter et al., 1983) . Electrophysiologic examination of the neuromuscular junction did not directly demonstrate presynaptic inhibition of neurotransmitter release by metalloendoprotease inhibitors, and biochemical metalloendoprotease assays could not be performed on the synaptic terminal. Consequently, we are examining the possibility in the retina that metalloendoprotease activity within the presynaptic terminal may be required for neurotransmitter release. A population of retinal neurons in Xenopus laevis accumulates ["Hlglycine by high affinity uptake and releases accumulated glycine in response to elevated K' in the extracellular medium (Rayborn et al., 1981) . The isolated retina preparation has several advantages as a model system for studying the requirement of metalloendoprotease activity during neurotransmitter release. The glycine-accumulating neurons are intact, unlike brain slice or synaptosome preparations, and [3H] glycine release can be directly and quantitatively assayed. The depolarization-induced release of retinal glycine is calcium dependent (Rayborn et al., 1981) . Finally, metalloendoprotease activity can be identified and characterized in the retina. (Fig. 3) . The inhibition of release by l,lO-phenanthroline was dose dependent (Fig. 4) . The concentration of l,lO-phenanthroline required to block release completely (100 pg/ml) is the same concentration required to completely inhibit the retinal metalloendoprotease (see Fig. 10 ). CBZ-L-Phenylalanine is a reversible inhibitor of metalloendoproteases (Burstein et al., 1974 Retinas preloaded with ["Hlglycine were incubated with phenanthroline at various concentrations for 20 min before transfer to successive changes of media at 3-min intervals. Aliquots of media were counted for released radioactivity. Note the progressive reduction in the amount of radioactivity released with increasing phenanthroline concentrations.
vented [3H]glycine
release in a dose-dependent manner, whereas L-phenylalanine, which has no effect on metalloendoprotease activity, had no effect on neurotransmitter release (Fig. 5) .
Metalloendoproteases will hydrolyze CBZ dipeptide amides only if the derivative contains a peptide bond hydrolyzed by this protease. Metalloendoproteases hydrolyze CBZ-Gly-Leuamide, CBZ-Ser-Leu-amide, and CBZ-Gly-Phe-amide, but not CBZ-Gly-Gly-amide (Morihara, 1974) . We tested these dipeptides for their effects on the depolarization-induced release of glycine, to determine whether their ability to block neurotransitter release paralleled the ability to interact with metalloendoproteases. The dipeptide CBZ-Gly-Phe-amide, which is a metalloendoprotease substrate, blocked depolarization-induced glycine release, whereas CBZ-Gly-Gly-amide, which is not metalloendoprotease substrate, had no effect (Figs. 6 and 7, top). The inhibition of ["Hlglycine release by CBZ-Gly-Phe-amide was reversible (Fig. 6) . CBZ-Gly-Phe-amide blocked release in a dose-dependent fashion (Fig. 7) . The dipeptide metalloendoprotease substrates CBZ-Gly-Leu-amide and CBZ-Ser-Leuamide similarly blocked depolarization-induced '0-o -0-o 2 ii dp 3-. . release by synthetic metalloendoprotease substrate is amino acid specific, dose dependent, and reversible. Identification and characterization of retinal metalloendoprotease. Assay of metalloendoprotease activity is based on hydrolysis of AAGLAN, a sensitive and specific fluorogenic synthetic protease substrate developed by Kam et al. (1979) . AAG-LAN contains the Gly-Leu bond hydrolyzed by metalloendoproteases. Hydrolysis of the peptide bond frees the fluorescent 2-aminobenzoyl group from intramolecular quenching by the 4-nitrobenzylamide.
Fluorescence therefore quantitatively reflects the amount of substrate hydrolyzed.
The Xenopus retina contains soluble and membrane-associated metalloendoprotease activities which hydrolyze this fluorogenic metalloendoprotease substrate. Hydrolysis of AAGLAN by the soluble metalloendoprotease was linear for at least 8 hr (Fig. 8) , was saturable with an apparent K,,, of approximately 0.5 mM (Fig. 9) , and was inhibited by the metal chelator l, lOphenanthroline with an I& of approximately 20 pg/ml (Fig.  10 ). An active site metalloendoprotease inhibitor, 2-(N-hydroxycarboxamide)-4-methylpentanoyl-L-Ala-Gly-amide (Nishino and Powers, 1979) , also inhibited the protease with an Icno of approximately 5 FM. Metalloendoprotease activity is found in both the cytoplasmic and pellet fractions of retinal homogenates. We do not know whether metalloendoprotease activity found in the pellet fraction is the same enzyme identified in the soluble fraction which is simply associated with the membranes, trapped in vesicles, or alternatively, a different metal- loendoprotease.
Studies are in progress to determine whether the soluble and membrane-associated retinal metalloendoproteases have different inhibitor specificities. Soluble (Orlowski et al., 1983) and membrane-associated (Orlowski and Wilk, 1981; Benuck et al., 1982; Matsas et al., 1983 ) metalloendoproteases have been documented extensively in brain.
Discussion
Metalloendoproteases are a class of soluble or membranebound proteases which are identified and characterized by specific inhibitors.
Zinc, present in the native enzyme, is required for catalytic activity, although other metals may also confer proteolytic activity to the apoenzyme (Chlebowski and Coleman, 1976) . The metal chelator, l,lO-phenanthroline, is a potent metalloendoprotease inhibitor and has received extensive use in studies of metalloendoproteases (Barrett, 1977 Fig. 4 ).
by chelating calcium since excess calcium added to the retinal preparation does not restore neurotransmitter release. The reversible metalloendoprotease inhibitor, CBZ-L-phenylalanine, likewise inhibited pH]glycine release at concentrations inhibiting metalloendoprotease (Burstein et al., 1974) , whereas L-phenylalanine, which has no effect on metalloendoproteases, had no effect on release.
The substrate specificities of metalloendoproteases are similar and have been examined extensively using synthetic dipeptide derivatives (Morihara, 1974; Barrett, 1977) . Metalloendoproteases hydrolyze peptide bonds on the amino termini of nonpolar aromatic amino acids such as phenylalanine and large aliphatic amino acids such as leucine. They will not hydrolyze the peptide bonds formed by the small aliphatic amino acid, glycine. Metalloendoproteases thus hydrolyze the dipeptide substrates CBZ-Gly-Phe-amide, CBZ-Gly-Leu-amide, and CBZ-Ser-Leu-amide, but not CBZ-Gly-Gly-amide. This paper presents evidence for the hypothesis that metalloendoproteases are involved in the release of transmitter substances at synapses. Our observations show that CBZ dipeptide amides, which are metalloendoprotease substrates, prevent [3H] glycine release whereas dipeptide derivatives, which are not metalloendoprotease substrates, have no effect. CBZ dipeptideamides, which are able to enter cells (Grinde et al., 1983) , inhibit ["Hlglycine release, possibly by competing with the natural substrates of the metalloendoproteases.
Inhibition of release by these dipeptide substrates is dose dependent, with concentrations causing half-maximal inhibition similar to the K,,, concentrations for metalloendoproteases (Morihara, 1974) . In addition to being amino acid specific and concentration dependent, dipeptide inhibition of transmitter release was re-
